Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial-Reference-Cited by-同舟云学术

Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial

Published:2021-10 Issue: Volume: Page:
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Heymach John V.^ORCID,Mitsudomi Tetsuya,Harpole David,Aperghis Mike,Jones Stephanie,Mann Helen,Fouad Tamer M.,Reck Martin^ORCID

Funder

AstraZeneca plc

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. National Comprehensive Cancer Network. NCCN Guidelines Version 5.2021 Non-Small Cell Lung Cancer. 2021. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 [Accessed 1 July 2021].

2. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer;Goldstraw;J Thorac Oncol,2016

3. Completely resected n0 non-small cell lung cancer: prognostic factors affecting long-term survival;Tantraworasin;ISRN Surg,2013

4. Recurrence after surgery in patients with NSCLC;Uramoto;Transl Lung Cancer Res,2014

5. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J Clin Oncol,2008

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: A retrospective study;Translational Oncology;2024-10

2. Adjuvant modern radiotherapy in resected pN2 NSCLC patients: results from a multicentre retrospective analysis on acute and late toxicity on behalf of AIRO thoracic oncology study group: the RAC-TAC study;La radiologia medica;2024-08-31

3. The role of immunotherapy in early-stage and metastatic NSCLC;Pathology and Oncology Research;2024-07-04

4. Contemporary Strategies: Incorporating Immunotherapy into Stage 3 Non-small Cell Lung Cancer Treatment;Tuberculosis and Respiratory Diseases;2024-07-01

5. Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2024-07